SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Gland Pharma falls after USFDA concludes inspection at Pashamylaram Facility with three observations

05 Aug 2024 Evaluate

Gland Pharma is currently trading at Rs. 2123.05, down by 4.75 points or 0.22% from its previous closing of Rs. 2127.80 on the BSE.

The scrip opened at Rs. 2000.05 and has touched a high and low of Rs. 2149.35 and Rs. 2000.05 respectively. So far 31509 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 2195.75 on 07-Feb-2024 and a 52 week low of Rs. 1,303.15 on 07-Aug-2023.

Last one week high and low of the scrip stood at Rs. 2182.00 and Rs. 2000.05 respectively. The current market cap of the company is Rs. 35166.26 crore.

The promoters holding in the company stood at 51.83%, while Institutions and Non-Institutions held 39.71% and 8.45% respectively.

United States Food and Drug Administration (USFDA) has conducted an un-announced inspection of Gland Pharma’s Pashamylaram Facility at Hyderabad for Good Manufacturing Practices (GMP) between July 25, 2024 and August 2, 2024.

The said inspection was concluded with three 483 Observations. These observations are procedural in nature. The corrective and preventive actions for these observations will be submitted to the US FDA within the stipulated period. The observations issued are neither repeated observations nor related to data integrity.

Gland Pharma develops, manufactures and markets complex injectables. The company sells its products primarily under a business-to-business model in many countries.


Gland Pharma Share Price

1795.80 59.80 (3.44%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×